New Entries Could Boost Generic Drug Image In Japan - JGA President
This article was originally published in PharmAsia News
Executive Summary
Japan Generics Association President Hiroyuki Sawai said the recent generics entries of Pfizer and Daiichi Sankyo could help boost the generic drug image in Japan. Sawai said the wall between innovative and generic drug makers is disappearing and the major drug makers will establish new quality and trust for the industry. Many Japanese generics manufacturers are small to mid-sized, and generic drugs are considered in Japan to be lower in quality than brand products. JGA has implemented a series of programs to emphasize the quality and safety of generic drugs. Sawai also said that compared to the EU and the U.S., Japan still lacks systemic support to stimulate generics use, and he expects the industry will grow further as the government implements promotional measures. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.